Latest / Community Health Media
Dr. Megan Kruse, Dr. Ryan Rader, & Dr. Praveen Vikas - DB11 & DB05 Change HER2+ Care
Metastatic triple-negative breast cancer has long been one of the most challenging breast cancer subtypes to treat. But with the emergence of ADCs, the treatment landscape is rapidly evolving.
In this in-depth discussion from ASCO 2026, Dr. Megan Kruse, Dr. Ryan Rader, and Dr. Praveen Vikas explore the latest advances in first-line treatment for metastatic TNBC, including the recently approved datopotamab deruxtecan and the growing role of sacituzumab govitecan.
The panel reviews key findings from the TROPION-Breast02 and ASCENT-03 trials, discusses overall survival and progression-free…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.